Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Association of PTEN and ARID1A Expression in Patients with Atypical Endometrial Hyperplasia and Concurrent Endometrioid Carcinoma: A Retrospective Cohort Study

View through CrossRef
Objective: Some endometrial biopsies from patients with atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) show concurrent endometrioid carcinoma (EC). Hysterectomy is the standard treatment for AH/EIN; however, hormonal therapy is also acceptable for women who wish to preserve fertility. Few studies have simultaneously evaluated the expressions of PTEN and ARID1A in endometrial biopsies to predict concurrent EC. This study aim evaluated whether the loss of PTEN and ARID1A expressions in endometrial biopsies indicate the presence of concurrent EC. Material and Methods: Endometrial biopsies from 46 patients with AH/EIN who underwent hysterectomy within 3 months between 2011 and 2021 were reviewed. Loss of or intact PTEN and ARID1A expressions was evaluated using immunohistochemistry. The presence or absence of EC in the hysterectomy specimen indicated the presence or absence of concurrent EC. Logistic regression analysis was used to determine associations. Results: Concurrent EC was found in 32.6% (15/46) of the patients. Loss of PTEN and ARID1A was observed in 54.3% and 8.7% of the endometrial biopsies, respectively. Endometrial biopsies with loss of PTEN expression had an insignificantly higher prevalence of concurrent EC than those with intact PTEN expression (44% versus [vs.] 19%, p-value=0.107). Loss and intact ARID1A expressions showed no difference in the prevalence of concurrent EC (25% vs. 33.3%, p-value=1). Multivariate analysis showed loss of PTEN tended to be associated with concurrent EC (odd ratio [OR]=2.38, 95% CI 0.52–10.96), while loss of ARIDA showed no evidence of association (OR=0.92, 95% CI=0.07–12.97). Conclusion: One-third of the endometrial biopsies with AH/EIN have concurrent EC. The loss of PTEN expression in AH/EIN may indicate the presence of concurrent cancer. However, further studies with larger sample sizes are needed to confirm the results.
Title: Association of PTEN and ARID1A Expression in Patients with Atypical Endometrial Hyperplasia and Concurrent Endometrioid Carcinoma: A Retrospective Cohort Study
Description:
Objective: Some endometrial biopsies from patients with atypical hyperplasia/endometrial intraepithelial neoplasia (AH/EIN) show concurrent endometrioid carcinoma (EC).
Hysterectomy is the standard treatment for AH/EIN; however, hormonal therapy is also acceptable for women who wish to preserve fertility.
Few studies have simultaneously evaluated the expressions of PTEN and ARID1A in endometrial biopsies to predict concurrent EC.
This study aim evaluated whether the loss of PTEN and ARID1A expressions in endometrial biopsies indicate the presence of concurrent EC.
Material and Methods: Endometrial biopsies from 46 patients with AH/EIN who underwent hysterectomy within 3 months between 2011 and 2021 were reviewed.
Loss of or intact PTEN and ARID1A expressions was evaluated using immunohistochemistry.
The presence or absence of EC in the hysterectomy specimen indicated the presence or absence of concurrent EC.
Logistic regression analysis was used to determine associations.
Results: Concurrent EC was found in 32.
6% (15/46) of the patients.
Loss of PTEN and ARID1A was observed in 54.
3% and 8.
7% of the endometrial biopsies, respectively.
Endometrial biopsies with loss of PTEN expression had an insignificantly higher prevalence of concurrent EC than those with intact PTEN expression (44% versus [vs.
] 19%, p-value=0.
107).
Loss and intact ARID1A expressions showed no difference in the prevalence of concurrent EC (25% vs.
33.
3%, p-value=1).
Multivariate analysis showed loss of PTEN tended to be associated with concurrent EC (odd ratio [OR]=2.
38, 95% CI 0.
52–10.
96), while loss of ARIDA showed no evidence of association (OR=0.
92, 95% CI=0.
07–12.
97).
Conclusion: One-third of the endometrial biopsies with AH/EIN have concurrent EC.
The loss of PTEN expression in AH/EIN may indicate the presence of concurrent cancer.
However, further studies with larger sample sizes are needed to confirm the results.

Related Results

Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Abstract 4697: The PI3K/mTOR pathway is a potential therapeutic target in cancers with ARID1A mutations
Abstract 4697: The PI3K/mTOR pathway is a potential therapeutic target in cancers with ARID1A mutations
Abstract The chromatin remodeling SWI/SNF complex is mutated in 20% of all cancers and ARID1A is the most frequently mutated subunit. However, the tumor suppressive ...
Abstract 294: Altered ARID1A expression in colorectal cancer
Abstract 294: Altered ARID1A expression in colorectal cancer
Abstract Background: ARID1A has been described as a tumor suppressor gene, participating in chromatin re-modeling, epithelial-mesenchymal-transition and many other c...
Abstract 214: ARID1A and ARID1B dependent proteomics
Abstract 214: ARID1A and ARID1B dependent proteomics
Abstract Protein sub-units of the SWI/SNF nucleosome and chromatin remodeling complexes are frequently mutated in cancer. The ARID1A and ARID1B DNA interacting compo...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract Introduction Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 6137: Development of ARID1A-deficient hepatocellular carcinoma in transgenic pigs
Abstract 6137: Development of ARID1A-deficient hepatocellular carcinoma in transgenic pigs
Abstract Hepatocellular carcinoma (HCC) is an aggressive disease with poor response to treatment at advanced stages. Frameshift and nonsense mutations in ARID1A, a s...
Promoter Methylation and Phosphorylation Status of PTEN in Taiwanese Breast Cancer.
Promoter Methylation and Phosphorylation Status of PTEN in Taiwanese Breast Cancer.
Abstract Background: The PTEN (phosphatase and tensin homolog deleted on chromosome Ten) gene is a novel candidate of tumor suppressor that plays an important role i...
Fonctions de la protéine suppresseur de tumeurs PTEN : régulation par les β-arrestines et par l’interaction intramoléculaire
Fonctions de la protéine suppresseur de tumeurs PTEN : régulation par les β-arrestines et par l’interaction intramoléculaire
La protéine suppresseur de tumeurs PTEN (Phosphatase and tensin deleted on chromosome 10) est une phosphatase lipidique. En déphosphorylant le phosphatidylinositol (3,4,5) trisphos...

Back to Top